^
2d
New P3 trial
|
Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib) • rocbrutinib (LP-168)
3d
Bendamustine combined with Zuberitamab (BZ) followed by Orelabrutinib combined with Zuberitamab (OZ) in the treatment of newly diagnosed marginal zone lymphoma:A Phase II prospective clinical study (ChiCTR2500115104)
P=N/A, N=74, Not yet recruiting, The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University
New trial
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Inokai (orelabrutinib) • bendamustine • Anruixi (zuberitamab)
3d
A prospective observational study of Orelabrutinib combined with anti-CD20 monoclonal antibody followed by Orelabrutinib maintenance as first-line treatment for MZ (ChiCTR2500113665)
P=N/A, N=40, Not yet recruiting, The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University
New trial
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Inokai (orelabrutinib)
3d
Rituximab, Lenalidomide, and Orelabrutinib Combination Regimen in the Treatment of marginal zone cell lymphoma: a Prospective, Single-Arm, Phase II Clinical Study (ChiCTR2500115204)
P2, N=46, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
New P2 trial
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
6d
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. (clinicaltrials.gov)
P2, N=23, Recruiting, The First Affiliated Hospital of Soochow University
New P2 trial
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Inokai (orelabrutinib)
13d
New P4 trial
|
Rituxan (rituximab) • Gazyva (obinutuzumab) • Inokai (orelabrutinib)
17d
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
P3, N=990, Not yet recruiting, Zenas BioPharma (USA), LLC | N=330 --> 990
Enrollment change
|
Inokai (orelabrutinib)
1m
New P3 trial
|
Inokai (orelabrutinib)
2ms
New P2 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
Rituxan (rituximab) • Inokai (orelabrutinib) • lisaftoclax (APG-2575)
2ms
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis (clinicaltrials.gov)
P3, N=705, Recruiting, Zenas BioPharma (USA), LLC | Initiation date: Sep 2025 --> Dec 2025 | Not yet recruiting --> Recruiting
Enrollment open • Trial initiation date
|
Inokai (orelabrutinib)
2ms
New trial
|
Inokai (orelabrutinib) • pomalidomide • Anruixi (zuberitamab)
2ms
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy (clinicaltrials.gov)
P2, N=79, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Initiation date: Jun 2025 --> Dec 2025
Trial initiation date
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib)